| Name | Title | Contact Details |
|---|
Tjoapack is a contract packaging organisation which specialises in developing innovative primary & secondary packaging solutions for the pharma supply chain.
Stason Pharmaceuticals Inc is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Guardian Pharmacy Services, headquartered in Atlanta, Georgia, is the nation’s third largest institutional pharmacy company and one of the fastest growing privately held companies in the state of Georgia. Founded in 2004, Guardian and its partner pharmacies focus on providing exceptional client service and patient care to long-term care customers in assisted living communities, skilled nursing facilities, hospice and behavioral health group homes. Guardian Pharmacy Services` business model allows partner pharmacies to operate as independent local businesses tailoring their services to the needs of customers in their respective markets. We take our responsibility to our customers and their residents very seriously, and always strive to make sure that every prescription we fill and every service we execute receives our utmost care and attention. In the end, customers are the winners as pharmacies devote more attention to them while still meeting the many demands of any business. Guardian is 100% committed to fostering a sustainable business driven by our core values, conducting business according to the Golden Rule; treating each other, our customers and residents fairly and honestly.
Aeterna Zentaris Inc. is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Company`s lead product, Macrilen™ (macimorelin), is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). Macrilen™ is currently marketed in the United States through a license agreement with Novo Nordisk and Aeterna Zentaris receives double-digit royalties on sales. Aeterna Zentaris owns all rights to macimorelin outside of the U.S. and Canada. Aeterna Zentaris is also leveraging the clinical success and compelling safety profile of macimorelin to develop it for the diagnosis of child-onset growth hormone deficiency (CGHD), an area of significant unmet need. The Company is actively pursuing business development opportunities for the commercialization of macimorelin in Europe and the rest of the world, in addition to other non-strategic assets to monetize their value.